3692 Stoklara Genel Bakış Bir yatırım holding şirketi olan Hansoh Pharmaceutical Group Company Limited, Çin Halk Cumhuriyeti'nde farmasötik ürünlerin araştırılması, geliştirilmesi, üretimi ve satışı ile ilgilenmektedir. Daha fazla detay
Ödüller Risk Analizi Tüm Risk Kontrollerini Gör Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
Hansoh Pharmaceutical Group Company Limited Rakipler Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Hansoh Pharmaceutical Group Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı HK$18.20 52 Haftanın En Yüksek Seviyesi HK$22.80 52 Haftanın En Düşük Seviyesi HK$11.18 Beta 0.63 1 Aylık Değişim -2.05% 3 Aylık Değişim -9.45% 1 Yıllık Değişim 26.56% 3 Yıllık Değişim -1.30% 5 Yıllık Değişim -29.73% Halka arzdan bu yana değişim -26.91%
Son Haberler & Güncellemeler
Hansoh Pharmaceutical Group Company Limited Announces the Fifth New Drug Application of Ameile (Aumolertinib Mesilate Tablets) Was Accepted by the National Medical Products Administration Nov 27
Hansoh Pharmaceutical Group Company Limited Announces the NMPA Has Granted Breakthrough-Therapy-Designated Drug for B7-H3-Targeted Antibody-Drug Conjugate HS-20093 Nov 01
Hansoh Pharmaceutical Group Company Limited Announces Phase III Registrational Trial AENEAS2 Evaluating Ameile in Combination with Chemotherapy for Patients with Locally Advanced or Metastatic EGFR-Mutated NSCLC Oct 22
New major risk - Revenue and earnings growth Oct 09
First half 2024 earnings released: EPS: CN¥0.46 (vs CN¥0.22 in 1H 2023) Sep 28
Upcoming dividend of HK$0.20 per share Sep 13 Daha fazla güncelleme görün
Hansoh Pharmaceutical Group Company Limited Announces the Fifth New Drug Application of Ameile (Aumolertinib Mesilate Tablets) Was Accepted by the National Medical Products Administration Nov 27
Hansoh Pharmaceutical Group Company Limited Announces the NMPA Has Granted Breakthrough-Therapy-Designated Drug for B7-H3-Targeted Antibody-Drug Conjugate HS-20093 Nov 01
Hansoh Pharmaceutical Group Company Limited Announces Phase III Registrational Trial AENEAS2 Evaluating Ameile in Combination with Chemotherapy for Patients with Locally Advanced or Metastatic EGFR-Mutated NSCLC Oct 22
New major risk - Revenue and earnings growth Oct 09
First half 2024 earnings released: EPS: CN¥0.46 (vs CN¥0.22 in 1H 2023) Sep 28
Upcoming dividend of HK$0.20 per share Sep 13
First half dividend of HK$0.20 announced Aug 29
New major risk - Revenue and earnings growth Aug 28
First half 2024 earnings released: EPS: CN¥0.46 (vs CN¥0.22 in 1H 2023) Aug 28
Hansoh Pharmaceutical Group Company Limited Announces an Interim Dividend for the Six Months Ended June 30, 2024, Payable on 30 October 2024 Aug 27
Hansoh Pharmaceutical Group Company Limited to Report First Half, 2024 Results on Aug 27, 2024 Aug 15
Now 22% undervalued after recent price drop Jul 30
Hansoh Pharmaceutical Group Company Limited Announces New Drug Application of Ammeile for the Adjuvant Treatment of Egfr Mutation-Positive Non-Small Cell Lung Cancer Accepted by the National Medical Products Administration of the People's Republic of China Jul 20
Now 22% undervalued Jul 15
Upcoming dividend of HK$0.14 per share Jun 12
Now 21% undervalued May 30
Full year 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.44 in FY 2022) May 01
Hansoh Pharmaceutical Group Company Limited, Annual General Meeting, Jun 13, 2024 May 01
Hansoh Pharmaceutical Group Company Limited Announces Executive Changes, Effective April 29, 2024 Apr 30
Hansoh Pharmaceutical Group Company Limited, Jiangsu Hansoh Pharmaceutical Group Company Limited and Shanghai Hansoh Biomedical Technology Company Limited Receives Grant of A Clinical Trial Notice Issued by the National Medical Products Administration of the People's Republic of China to Be Used for the Treatment of Advanced Non-Small Cell Lung Cancer Apr 03
Full year 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.44 in FY 2022) Mar 27
Hansoh Pharmaceutical Group Company Limited to Report Fiscal Year 2023 Results on Mar 26, 2024 Mar 15
Now 24% undervalued after recent price drop Mar 05
Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of HS-10509 Tablets Jan 17
Now 20% undervalued Jan 15
Shanghai Hansoh Biomedical Technology Company Limited and Jiangsu Hansoh Pharmaceutical Group Company Limited Receives Clinical Trial Notice Nov 11
Investor sentiment improves as stock rises 24% Oct 28
Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of Hs-20106 Injections Oct 20
Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-20105" Sep 26
Upcoming dividend of HK$0.071 per share at 1.4% yield Sep 08
Hansoh Pharmaceutical Group Company Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 28 September 2023 Sep 02
First half 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in 1H 2022) Sep 01
Hansoh Pharmaceutical Group Company Limited to Report Q2, 2023 Results on Aug 31, 2023 Aug 22
Investor sentiment deteriorates as stock falls 19% Aug 07
Now 25% undervalued after recent price drop Aug 02
Hansoh Pharmaceutical Group Company Limited Announces New Drug Application of Ibrexafungerp Tablets Accepted by the National Medical Products Administration Jul 23
Hansoh Pharmaceutical Group Company Limited Announces HS-10518 Capsules A Category 1 Innovative Drug, Has Been Granted A Clinical Trial Notice Jun 30
Hansoh Pharmaceutical Group Company Limited Provides Update on Clinical Trial Notice of HS-10516 Capsules Jun 14
Hansoh (Shanghai) Healthtech Company Limited Obtains an Exclusive License from Biotheus Inc Jun 06
Upcoming dividend of HK$0.05 per share at 0.7% yield May 29
Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-10506 Tablets" May 06
Full year 2022 earnings released: EPS: CN¥0.44 (vs CN¥0.46 in FY 2021) Mar 28
Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Approval of Oral Small Molecule 3CL Protease Inhibitor Jan 18
Hansoh Pharmaceutical Group Company Limited Announces That " Hs-10390 Tablets " Has Been Granted A Clinical Trial Notice Issued by the National Medical Products Administration of the People's Republic of China Jan 10
Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-10502 Tablets" Dec 29
Hansoh Pharmaceutical Group Company Limited Announces European Medicines Agency Accepts Review of EQRx's Marketing Authorization Application for aumolertinib Dec 04
Insufficient new directors Nov 16
Investor sentiment improved over the past week Oct 18
Investor sentiment deteriorated over the past week Sep 03
Upcoming dividend of HK$0.05 per share Sep 01
Hansoh Pharmaceutical Group Company Limited Announces Interim Dividend for the Six Months Ended June 30, 2022, Payable on 30 September 2022 Aug 27
First half 2022 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in 1H 2021) Aug 27
Hansoh Pharmaceutical Group Company Limited to Report First Half, 2022 Results on Aug 26, 2022 Aug 17
Investor sentiment improved over the past week Jun 25
Upcoming dividend of HK$0.09 per share Jun 09
Insufficient new directors Jun 02
Hansoh Pharmaceutical Group Company Limited Proposes Final Ordinary Dividend for the Financial Year End December 31, 2021, Payable on July 15, 2022 May 24
Hansoh Pharmaceutical Group Company Limited Announces New Drug Application for the New Indication of Pegmolesatide Injections May 12
Full year 2021 earnings released: EPS: CN¥0.46 (vs CN¥0.44 in FY 2020) Apr 30
Full year 2021 earnings released: EPS: CN¥0.46 (vs CN¥0.44 in FY 2020) Mar 31
Hansoh Pharmaceutical Group Company Limited Announces Final Dividend for the Year Ended December 31, 2021, payable on July 5, 2022 Mar 30
Investor sentiment deteriorated over the past week Mar 16
Investor sentiment deteriorated over the past week Jan 28
Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-10383 tablets" Dec 29
Hansoh Pharmaceutical Group Company Limited Announces That "Ibrexafungerp Tablets" Has Been Granted A Clinical Trial Dec 16
Less than half of directors are independent Sep 10
Non-Executive Director Cuifang Ma has left the company Sep 07
First half 2021 earnings released: EPS CN¥0.22 (vs CN¥0.21 in 1H 2020) Aug 29
Investor sentiment deteriorated over the past week Jul 28
Hansoh Pharmaceutical Group Company Limited Receives Approval by the National Medical Products Administration of the People ' S Republic of China for Class 1 Innovative Drug Tenofovir Amibufenamide Tablets Jun 24
Investor sentiment improved over the past week May 22
Hansoh Pharmaceutical Group Company Limited Announces New Drug Application of Ameile for the First-Line Treatment of Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer May 14
Hansoh Pharmaceutical Group Company Limited Announces FDA Tentative Approval of "Bortezomib for Injection" May 11
Full year 2020 earnings released: EPS CN¥0.44 (vs CN¥0.47 in FY 2019) Apr 29
Hansoh Pharmaceutical Group Company Limited Recommends a Final Dividend for the Year Ended December 31, 2020, Payable on July 5, 2021 Apr 28
Full year 2020 earnings released: EPS CN¥0.44 (vs CN¥0.47 in FY 2019) Mar 31
Hansoh Pharmaceutical Group Company Limited to Report Fiscal Year 2020 Results on Mar 30, 2021 Mar 18
SCYNEXIS and Hansoh Pharma Announce Licensing Agreement and Strategic Partnership for Ibrexafungerp in China Feb 18
New 90-day high: HK$40.40 Jan 05
Hansoh Pharmaceutical Group Company Limited Announces Drug Registration Approval of Saxagliptin Tablets Nov 02
Hansoh Pharmaceutical Group Company Limited Announces Acceptance of Biologics License Application of Inebilizumab Injections by National Medical Products Administration Oct 15
First half earnings released Sep 18
First half earnings released Aug 27
Hansoh Pharmaceutical Group Company Limited to Report First Half, 2020 Results on Aug 26, 2020 Aug 18
New 90-day high - HK$39.50 Jul 23 Hissedar Getirileri 3692 HK Pharmaceuticals HK Pazar 7D -1.5% 0.2% 1.5% 1Y 26.6% -3.7% 20.6%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: 3692 geçen yıl % -3.7 oranında getiri sağlayan Hong Kong Pharmaceuticals sektörünü aştı.
Getiri vs Piyasa: 3692 geçen yıl % 20.6 oranında getiri sağlayan Hong Kong Piyasasını aştı.
Fiyat Oynaklığı Is 3692's price volatile compared to industry and market? 3692 volatility 3692 Average Weekly Movement 6.1% Pharmaceuticals Industry Average Movement 6.4% Market Average Movement 8.8% 10% most volatile stocks in HK Market 18.6% 10% least volatile stocks in HK Market 4.0%
İstikrarlı Hisse Senedi Fiyatı: 3692 son 3 ayda önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: 3692 'nin haftalık oynaklığı ( 6% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında Bir yatırım holding şirketi olan Hansoh Pharmaceutical Group Company Limited, Çin Halk Cumhuriyeti'nde farmasötik ürünlerin araştırılması, geliştirilmesi, üretimi ve satışı ile ilgilenmektedir. Şirket, anti-tümör, anti-enfeksiyon, merkezi sinir sistemi hastalıkları, onkoloji, metabolik ve otoimmün hastalıklar vb. dahil olmak üzere terapötik alanlar için ürünler sunmaktadır.
Daha fazla göster Hansoh Pharmaceutical Group Company Limited Temel Bilgiler Özeti Hansoh Pharmaceutical Group'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? 3692 temel i̇stati̇sti̇kler Piyasa değeri HK$108.00b Kazançlar(TTM ) HK$5.02b Gelir(TTM ) HK$12.88b
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) 3692 gelir tablosu (TTM ) Gelir CN¥12.10b Gelir Maliyeti CN¥1.09b Brüt Kâr CN¥11.01b Diğer Giderler CN¥6.30b Kazançlar CN¥4.71b
Temettüler
2.1% Mevcut Temettü Verimi
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2024/12/25 13:34 Gün Sonu Hisse Fiyatı 2024/12/24 00:00 Kazançlar 2024/06/30 Yıllık Kazançlar 2023/12/31
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.
Analist Kaynakları Hansoh Pharmaceutical Group Company Limited 32 Bu analistlerden 20, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum Sharon Shi BOCI Research Ltd. Bo Li BofA Global Research Jin Zhang China International Capital Corporation Limited
Göster 29 daha fazla analist 
